Filing Analysis
Sanuwave Health, Inc. issued a press release on June 16, 2026, providing updated financial guidance for the quarter ending June 30, 2026.
📋 Key Facts
- The company issued updated guidance for the quarter ended June 30, 2026.
- The announcement was made via a press release (Exhibit 99.1) on June 16, 2026.
- The filing is submitted under Item 7.01 (Regulation FD Disclosure), meaning the information is 'furnished' rather than 'filed'.
Sanuwave Health, Inc. reported the results of its 2026 annual meeting of stockholders held on June 11, 2026. Stockholders voted to elect five directors, ratify the appointment of Baker Tilly US, LLP as the independent auditor, and approve executive compensation in a non-binding vote.
📋 Key Facts
- Annual meeting of stockholders held on June 11, 2026.
- Five directors elected: Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, and James Tyler.
- Baker Tilly US, LLP ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation was approved via an advisory, non-binding vote (4,666,444 votes for vs 385,238 against).
SANUWAVE Health, Inc. announced its financial results for the first quarter ended March 31, 2026. The company has scheduled a conference call for May 13, 2026, to discuss the results and provide a business update.
📋 Key Facts
- Financial results for the first quarter ended March 31, 2026, were released on May 12, 2026.
- A business update conference call is scheduled for May 13, 2026, at 8:30 am EST.
- The filing includes Exhibit 99.1, which is the press release detailing the financial performance.
- The information is furnished under Item 2.02 and is not deemed 'filed' for regulatory purposes.
SANUWAVE Health, Inc. announced preliminary financial results for the first quarter ended March 31, 2026, via a press release on April 16, 2026. The disclosure was made under Item 2.02, providing a routine update on the company's financial condition.
📋 Key Facts
- Preliminary financial results for the quarter ended March 31, 2026, were announced on April 16, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The registrant is listed on The Nasdaq Stock Market LLC under the ticker SNWV.
SANUWAVE Health, Inc. issued a press release on March 26, 2026, announcing its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company scheduled a follow-up conference call and business update for March 27, 2026.
📋 Key Facts
- Financial results announced for Q4 and fiscal year ended December 31, 2025.
- Conference call scheduled for March 27, 2026, at 8:30 am EST.
- The filing includes Exhibit 99.1, the press release detailing the financial performance.
- The report was signed by Peter Sorensen, Chief Financial Officer.
SANUWAVE Health, Inc. has determined that its audited financial statements for fiscal year 2024 and unaudited statements for all quarters in 2024 and 2025 can no longer be relied upon due to unrecorded sales and use tax liabilities. The company expects to record a significant increase in liabilities and expenses following a nexus study that identified historical tax obligations.
🚩 Red Flags
- Non-reliance on multiple years of previously issued audited and unaudited financial statements.
- Significant unrecorded tax liabilities ($4.9M-$5.2M) relative to typical micro-cap balance sheets.
- Potential identification of new material weaknesses in internal controls.
- The issue spans the tenure of both current (Baker Tilly) and former (Marcum) auditors.
📋 Key Facts
- Item 4.02 filing triggered by a third-party sales and use tax nexus study.
- Affected periods include the full year 2024 and the first three quarters of both 2024 and 2025.
- Estimated aggregate increase in reported liabilities is between $4.9 million and $5.2 million as of December 31, 2025.
- Estimated increase in expenses for 2024 is $1.6 million to $1.8 million, and for 2025 is $1.7 million to $1.9 million.
- Management is evaluating whether this matter results in additional material weaknesses in internal control over financial reporting.
- The restated figures will be included in the 2025 Form 10-K.